Correction to: Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience

Affiliations

• ¹ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy. [email protected].
• ² Department of Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. [email protected].
• ³ Haematology, Department of Cellular Biotechnologies and Haematology, Sapienza University of Rome, Rome, Italy.